Clinical Trial Update: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents [Phase 3]

View source ↗

Summary

Phase 3 trial of deutetrabenazine (TEV-50717) for dyskinesia in children and adolescents with cerebral palsy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Palsy
• Dyskinesia

Drugs mentioned

• TEV-50717

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Cerebral Palsy, Dyskinetic | Phase 3 | Status: COMPLETED | Results posted: 2023-09-08